METHODS AND COMPOSITIONS FOR ALTERING HEALTH, WELLBEING, AND LIFESPAN
First Claim
1. A method for modulating the lifespan of a cell, tissue, organ or organism, or of increasing or decreasing cellular respiration and/or capacity and/or biogenesis of mitochondria in a cell, tissue, organ or organism, comprising contacting the cell, tissue, organ or organism with at least one lifespan modulating agent selected from the group consisting of:
- idebenone, or an analog or derivative thereof;
a cocoa extract;
a coffee cherry extract;
quinic acid, or an analog or derivative thereof;
ferulic acid, or an analog or derivative thereof;
a proanthocyanidin, anthocyanidin, procyanidin, or cyanidin;
chlorogenic acid, or an analog or derivative thereof;
a tea extract;
orresveratrol or a composition derived from or chemically related to resveratrol.
1 Assignment
0 Petitions
Accused Products
Abstract
Described herein are the results of comprehensive genetic expression and other molecular analysis of the effect of antioxidants on biological systems, including specifically different human cells. Based on these analyses, methods and compositions are described for modifying or influencing the lifespan of cells, tissues, organs, and organisms. In various embodiments, there are provided methods for modulating the activity of the gene maintenance process in order to influence the length and/or structural integrity of the telomere in living cells, as well as methods for modulating the rate/efficiency of the cellular respiration provided by the mitochondria, mitochondrial biogenesis, and maintenance of the mitochondrial membrane potential. Exemplary lifespan altering compounds include natural and synthetic antioxidants, such as plant antioxidant and polyphenol compounds derived from coffee cherry, tea, berry, and so forth, including but not limited to caffeic acid, chlorogenic acid, ferulic acid, quinic acid, proanthocyanidins, ubiquinone, idebenone, or a synthetic form or derivatives thereof.
148 Citations
72 Claims
-
1. A method for modulating the lifespan of a cell, tissue, organ or organism, or of increasing or decreasing cellular respiration and/or capacity and/or biogenesis of mitochondria in a cell, tissue, organ or organism, comprising contacting the cell, tissue, organ or organism with at least one lifespan modulating agent selected from the group consisting of:
-
idebenone, or an analog or derivative thereof; a cocoa extract; a coffee cherry extract; quinic acid, or an analog or derivative thereof; ferulic acid, or an analog or derivative thereof; a proanthocyanidin, anthocyanidin, procyanidin, or cyanidin; chlorogenic acid, or an analog or derivative thereof; a tea extract;
orresveratrol or a composition derived from or chemically related to resveratrol. - View Dependent Claims (6, 9, 10, 36, 37, 38)
-
-
2-5. -5. (canceled)
-
7-8. -8. (canceled)
-
11-26. -26. (canceled)
- 27. A method for modulating response or resistance to stress of a cell, tissue, organ or organism, comprising modulating the level and/or activity of at least one gene selected from the group consisting of those listed in Data Table 7 and those listed as part of Array 2.
-
31-35. -35. (canceled)
- 39. A method for modulating, preventing, delaying, or reversing acute cell death or apoptosis, or prolonging the survival of a cell, tissue, organ or organism comprising modulating the level and/or activity of at least one gene selected from the group consisting of those listed in Data Table 7 and those listed as part of Array 2.
-
41. A method for modulating, enhancing, maintaining or producing a more youthful or function of the skin and/or associated tissues, comprising modulating the level and/or activity of at least one gene selected from the group consisting of those listed in Data Table 7 and those listed as part of Array 2.
-
42. (cancel)
-
43. A collection of lifespan-influencing nucleic acid molecules, which collection comprises a plurality of nucleic acid molecules selected from those listed in Data Table 7 or Array 2, or fragments of those listed in Data Table 7 or Array 2.
-
44-45. -45. (canceled)
-
47-48. -48. (canceled)
-
49. A method of screening compounds useful for modulating lifespan, comprising:
-
contacting a test compound with a host cell expresses a lifespan-influencing protein encoded by an isolated nucleic acid molecule listed in Data Table 7 or listed as part of Array 2 and detecting a change in the expression of the nucleotide sequence or a change in activity of encoded protein, wherein such a change indicates the test compound is useful for modulating lifespan. - View Dependent Claims (50)
-
-
51. (canceled)
-
52. A method for identifying an agent with potential to influence mitochondrial damage, comprising:
-
contacting an cell with an agent; and detecting the level of a nucleic acid molecule corresponding to (1) ACTB, BCL2, BCL2L1, CDKN2A, COX10, COX18, CPT1B, CPT2, DNAJC19, EGF, EGR2, FIS1, GAPDH, GRPEL1, HSP90AA1, LRPPRC, MFN1, MFN2, NOS3, OPA1, PARP3, PARP4, PPARGC1A, SIRT2, SIRT4, SLC25A1, SLC25A1, SLC24A2, SLC25A3, SLC25A4, SCL25A5, SLC25A10, SLC25A12, SLC25A13, SLC25A14, SLC25A15, SLC25A16, SLC25A17, SLC25A19, SLC25A2, SLC25A20, SLC25A21, SLC25A22, SLC25A23, SLC25A24, SLC25A25, SLC25A27, SLC25A3, SLC25A30, SLC25A31, SLC25A37, SLC25A4, SLC25A5, TIMM10, TIMM17A, TIMM17B, TIMM22, TIMM23, TIMM44, TIMM50, TIMM8A, TIMM8B, TIMM9, TOMM20, TOMM22, TOMM34, TOMM40, TOMM40L, TOMM70A, UCP1, UCP2, UCP3 or another gene indicated herein as beneficial for mitochondrial health or maintenance when increased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein an increase in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to reverse or inhibit mitochondrial damage;
or(2) AIFM2, AIP, BAK1, BBC3, BID, BNIP3, CLK1, HSPA1A, HSPA1B, HSPA1L, IMMP1L, IMMP2L, MIPEP, PARP1, PARP2, PMAIP1, RPL13A, SOD1, SOD2, SFN, SH3GLB1, UXT or another gene indicated herein as beneficial for mitochondrial health or maintenance when decreased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein a decrease in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to reverse or inhibit mitochondrial damage;
or(3) ACTB, BCL2, BCL2L1, CDKN2A, COX10, COX18, CPT1B, CPT2, DNAJC19, EGF, EGR2, FIS1, GAPDH, GRPEL1, HSP90AA1, LRPPRC, MFN1, MFN2, NOS3, OPA1, PARP3, PARP4, PPARGC1A, SIRT2, SIRT4, SLC25A1, SLC25A1, SLC24A2, SLC25A3, SLC25A4, SCL25A5, SLC25A10, SLC25A12, SLC25A13, SLC25A14, SLC25A15, SLC25A16, SLC25A17, SLC25A19, SLC25A2, SLC25A20, SLC25A21, SLC25A22, SLC25A23, SLC25A24, SLC25A25, SLC25A27, SLC25A3, SLC25A30, SLC25A31, SLC25A37, SLC25A4, SLC25A5, TIMM10, TIMM17A, TIMM17B, TIMM22, TIMM23, TIMM44, TIMM50, TIMM8A, TIMM8B, TIMM9, TOMM20, TOMM22, TOMM34, TOMM40, TOMM40L, TOMM70A, UCP1, UCP2, UCP3 or another gene indicated herein as beneficial for mitochondrial health or maintenance when increased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein a decrease in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to increase or accelerate mitochondrial damage;
or(4) AIFM2, AIP, BAK1, BBC3, BID, BNIP3, CLK1, HSPA1A, HSPA1B, HSPA1L, IMMP1L, IMMP2L, MIPEP, PARP1, PARP2, PMAIP1, RPL13A, SODI, SOD2, SFN, SH3GLB1, UXT or another gene indicated herein as beneficial for mitochondrial health or maintenance when decreased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein an increase in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to increase or accelerate mitochondrial damage. - View Dependent Claims (56)
-
-
53-55. -55. (canceled)
-
57. A method for identifying an agent with potential to influence DNA damage or telomere shortening, comprising:
-
contacting an cell with an agent; and detecting the level of a nucleic acid molecule corresponding to; (1) AK3, APEX1, APEX2, ATF2, ATM, ATR, ATRX, BARDI, BLM, BRIP1, CCNH, CDK7, CDKN2A, CHEK1, CHEK2, CSF2, CTPS, DDB1, DDB2, DHFR, DMC1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, ERCC8, EXO1, FANCA, FANCC, FANCF, FANCG, FEN1, GADD45A, GADD45G, GTF2H1, GTF2H2, GTF2H3, GTF2H4, JUN, LIG1, LIG3, LIG4, MAP2K6, MAPKAPK2, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH4, MSH5, MSH6, NBN, NEIL1, NEIL2, NEIL3, NFKB1, NFKBIA, HK1, NUDT1, NUDT2, ODC1, PAPSS1, PAPSS2, PARP1, PARP3, PCNA, PMS1, PMS2, PNKP, POLB, POLD3, POLE, POLI, POLL, PRKDC, RAD1, RAD18, RAD21, RAD23A, RAD50, RAD51C, RAD51L1, RAD51L3, RAD52, RAD54B, RAD54L, RBBP8, SESN1, SLC23A2, TDG, TYMS, UBE2V2, UNG2, WRN, XAB2, XPA, XPC, XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC6, ZNRD1 or another gene indicated herein as beneficial for DNA or telomere maintenance when increased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein an increase in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to reverse or inhibit DNA damage or telomere shortening;
or(2) B2M, BRCA1, BRCA2, BTG2, CIDEA, CIDEB, DDIT3, DKC1, GTSE1, MDM2, PCBP4, PDCD8, PINX1, PPPIR15A, RAD17, RELA, TELO2, TEP1 or another gene indicated herein as beneficial for DNA or telomere maintenance when decreased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein a decrease in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to reverse or inhibit DNA damage or telomere shortening;
or(3) AK3, APEX1, APEX2, ATF2, ATM, ATR, ATRX, BARD1, BLM, BRIP1, CCNH, CDK7, CDKN2A, CHEK1, CHEK2, CSF2, CTPS, DDB1, DDB2, DHFR, DMC1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, ERCC8, EXO1, FANCA, FANCC, FANCF, FANCG, FEN1, GADD45A, GADD45G, GTF2H1, GTF2H2, GTF2H3, GTF2H4, JUN, LIG1, LIG3, LIG4, MAP2K6, MAPKAPK2, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH4, MSH5, MSH6, NBN, NEIL1, NEIL2, NEIL3, NFKB1, NFKB1A, HK1, NUDT1, NUDT2, ODC1, PAPSS1, PAPSS2, PARP1, PARP3, PCNA, PMS1, PMS2, PNKP, POLB, POLD3, POLE, POLI, POLL, PRKDC, RAD1, RAD18, RAD21, RAD23A, RAD50, RAD51C, RAD51L1, RAD51L3, RAD52, RAD54B, RAD54L, RBBP8, SESN1, SLC23A2, TDG, TYMS, UBE2V2, UNG2, WRN, XAB2, XPA, XPC, XRCC1, XRCC2, XRCC3, XRCC4, XRCC5, XRCC6, ZNRD1 or another gene indicated herein as beneficial for DNA or telomere maintenance when increased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein a decrease in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to accelerate or cause or enhance DNA damage or telomere shortening;
or(4) B2M, BRCA1, BRCA2, BTG2, CIDEA, CIDEB, DDIT3, DKC1, GTSE1, MDM2, PCBP4, PDCD8, PINX1, PPP1R15A, RAD17, RELA, TELO2, TEP1 or another gene indicated herein as beneficial for DNA or telomere maintenance when decreased, or the level or activity of a protein encoded thereby, in the presence and absence of the agent, wherein an increase in the level or activity in the presence of the agent as compared to in the absence of the agent indicates that the agent has potential to accelerate or cause or enhance DNA damage or telomere shortening.
-
-
58-60. -60. (canceled)
- 61. A method inducing expression of TERT, POT1, TPP1 and TERF2 in a cell, by applying to the cell or an organism comprising the cell a composition comprising between about 0.000001% and about 10% (by weight) coffee cherry extract.
-
62. (canceled)
-
64-65. -65. (canceled)
-
66. A method inducing expression of PARP1, BCL2 and p53 in a cell, by applying to the cell or an organism comprising the cell a composition comprising between about 0.000001% and about 10% (by weight) coffee cherry extract.
-
67-68. -68. (canceled)
-
69. A method of inducing expression of NOS2A, NOS1, and NOS3 in a cell, by applying to the cell or an organism comprising the cell a composition comprising between about 0.000001% and about 10% (by weight) coffee cherry extract.
-
70. (canceled)
-
71. A method of inducing expression of CCL4L1 in a cell, by applying to the cell or an organism comprising the cell a composition comprising between about 0.000001% and about 10% (by weight) coffee cherry extract.
-
72-73. -73. (canceled)
Specification